In high-gross-margin specialty pharma (≥85% GM), once a company's revenue exceeds its fixed post-launch cost base (SG&A + R&D + SBC, which are largely flat after peak launch spend), OCF inflection is faster and sharper than consensus models typically predict. Because SG&A, SBC, and R&D do not scale with incremental revenue — unlike in SaaS or marketplaces where COGS and sales costs partially scale — virtually all incremental gross profit (≥85 cents per dollar of new revenue) flows directly to operating income and OCF. The result is that the quarterly OCF can swing from negative to strongly positive in a single quarter, catching management guidance and analyst models that use gradual step-down assumptions.
The corollary: consensus and management models that forecast OCF breakeven "next year" consistently undershoot when the revenue-cost crossover occurs even one quarter early, because the fixed-cost structure means the entire annual shortfall collapses at once rather than linearly.
When modeling OCF inflection for specialty pharma companies with ≥85% gross margins: (1) track quarterly SG&A and R&D as absolute dollars, not as % of revenue — if they are flattening or declining, the operating leverage is fully loaded; (2) estimate the revenue level at which quarterly gross profit = total operating expenses; (3) once that crossover quarter is identified, model the OCF swing as (incremental revenue × GM%) rather than a smooth deceleration of losses. Expect management and consensus to be 1-2 quarters late on the inflection. This creates an asymmetric opportunity: if a specialty pharma company is within $10-15M quarterly revenue of its fixed-cost coverage level, a beat on the top line likely generates a disproportionate OCF surprise.